JNJ-64530440 (JNJ-0440), A Novel, Class N Capsid Assembly Modulator (CAM-N): Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Ascending Doses in Patients with Chronic Hepatitis B | ||
| | ||
| | AASLD 2019 Nov 8-11 Boston Ed Gane1, Christian Schwabe2, Oliver Lenz3, Thierry Verbinnen3, Willem Talloen3, Thomas N. Kakuda4, Chris Westland4, Megha Patel4, Jeysen Yogaratnam4*, Leonard Dragone4and Pieter Van Remoortere5 1New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand; 2Auckland Clinical Studies, Auckland, New Zealand; 3Janssen Pharmaceutica NV, Beerse, Belgium; 4Janssen BioPharma Inc., South San Francisco, CA, USA; 5Janssen Pharmaceuticals, Titusville, NJ, USA; *J. Yogaratnam is no longer with Janssen Biopharma        | |
| | ||
